Ponazuril CAS NO 69004-04-2 Inquire about Ponazuril

Tecoland supplies Ponazuril bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Ponazuril is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Ponazuril?

Ponazuril (INN), sold by Merial, Inc., now part of Boehringer Ingelheim, under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

Mechanism of Action:

Antiprotozoal drug. Coccidiostat. Ponazuril (also known as toltrazuril sulfone) is a metabolite of the poultry antiprotozoal drug toltrazuril. Ponazuril is a triazine-based drug that acts to inhibit enzyme systems in protozoa and/or decreasing pyrimidine synthesis. It is specific for apicomplexan organisms because the action attacks the apicoplast organelle in protozoa. This action produces a specific effect as an antiprotozoal agent without affecting other organisms. It has high oral absorption in horses. The half-life data has been conflicting for horses with different studies reporting 1.6 days, 2.5 days, and 4.5 days. The half-life is 2.4 hours in cattle and 5.6 days in pigs. One week of daily dosing in horses is needed to reach steady-state concentrations. A level of 100 ng/mL is believed to be necessary to prevent and treat infections caused by Sarcocystis neurona.

Ponazuril Side effects:

● The most common side effects are mild gastro-intestinal upset including vomiting and diarrhea.
● Keratoconjunctivitis sicca (KCS) has been reported in some dogs, particularly in breeds with a predisposition to KCS.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.